<p>➀ The study introduces a biomimetic nanovaccine (AECM@PC7A) that combines IFN-γ-treated tumor cell membranes with a synthetic adjuvant (PC7A) to enhance neoantigen presentation and activate the STING pathway, addressing limitations of conventional cancer vaccines;</p><p>➁ In preclinical models, the vaccine triggered robust T-cell responses, reduced tumor growth and metastasis, and demonstrated synergy with immune checkpoint inhibitors, leading to prolonged survival and immune memory;</p><p>➂ The platform offers a scalable approach for personalized immunotherapy by leveraging tumor-specific neoantigens and simplified manufacturing processes, showing promise for clinical translation.</p>